In line with these observations, our study identified BMI, blood pressure, CRP, and renal insufficiency as factors associated with DR, and highlighted immune–inflammatory/metabolic pathways and candidate druggable nodes (e.g., LY9, WWP2, ARHGAP1) that may enable cross-complication stratification and intervention. This evidence concerns the gene ARHGAP1 and Renal insufficiency.